Wednesday, June 8, 2011

Anthem boosts coverage of XDx heart transplant test

Anthem Blue Cross and Blue Shield, the single largest commerical insurer in the United States, will systematically cover heart transplant patients’ use of a test from Brisbane’s XDx Inc. that determines the risk of transplant rejection.
The AlloMap blood test from privately held XDx measures expression levels of 20 genes, allowing doctors to skip invasive tissue-sampling biopsies to determine if a transplanted heart is being rejected.
Anthem’s determination that the test is “medically necessary” is an important milestone for XDx, meaning that the test is covered systematically and not just on a case-by-case basis.

No comments:

Post a Comment